Results 71 to 80 of about 64,314 (239)

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park   +19 more
wiley   +1 more source

Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement

open access: yesJournal of Pediatrics: Clinical Practice
Objective: The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease trial was a phase 3, placebo-controlled, randomized trial that evaluated etanercept use for acute Kawasaki disease (KD).
Ryan Rogers, MD   +3 more
doaj   +1 more source

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

open access: yesJournal of Infection and Public Health
Background: The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB.
Abdulaziz Boqaeid   +9 more
doaj   +1 more source

Etanercept-Induced Encephalopathy in a 7-Year-Old Child

open access: yes, 2011
Adverse events were reported in various patients treated with etanercept, including infections (sepsis and tuberculosis), malignancies (e.g., lymphoma), demyelinating disorders, and autoimmune diseases.
Burak Tatlı   +9 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Etanercept attenuates liver damage in mice with AOM-induced ALF.

open access: yes, 2013
Etanercept was administered 30 min before AOM. Representative liver sections from (A) saline-treated control mice, (B) AOM-induced ALF comatose mice and (C and D) etanercept-treated ALF mice.
Mireille Bélanger (298649)   +5 more
core   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Effect of IT Etanercept on Adjuvant Arthritis

open access: yes, 2013
Rats were immunized with CFA on day 0 and treated with IT etanercept (100 or 300 μg q.o.d.) beginning on day 1. (A) IT etanercept (Etan) significantly decreased paw swelling (*p = 0.001 for IT saline compared with either IT etanercept group) (
Camille I Svensson (65493)   +7 more
core   +1 more source

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis

open access: yes
Arthritis &Rheumatology, EarlyView.
Lilach Shkolnik Arad, Gleb Slobodin
wiley   +1 more source

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy